Obesity Overweight
Conditions
Interventions
DRUG: Bimagrumab(Other Name: LY3985863)
Administered SC
DRUG: Tirzepatide(Other Name: LY3298176)
Administered SC
DRUG: Bimagrumab Placebo
Administered SC
DRUG: Tirzepatide Placebo
Administered
Sponsors
Masaki Takeshi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: -Have type 2 diabetes -Have a BMI of >=27 kilograms per square meter (kg/m2) -Have had a stable body weight for the 3 months prior to randomization (<5% body weight gain and/or loss)
Exclusion criteria
Exclusion criteria: -Have a prior or planned surgical treatment for obesity, -Have type 1 diabetes, latent autoimmune diabetes, or history of ketoacidosis or hyperosmolar state or coma -Have poorly controlled hypertension -Have any of the following cardiovascular conditions within 3 months prior to screening: * acute myocardial infarction * cerebrovascular accident (stroke) * unstable angina, or * hospitalization due to congestive heart failure -Have a history of New York Heart Association (NYHA) Functional Classification III or IV congestive heart failure -Have ongoing or a history of frequent intermittent or chronic tachyarrhythmia syndromes -Have ongoing or a history of bradyarrhythmias other than sinus bradycardia -Have renal impairment -Have a history of symptomatic gallbladder disease within the past 2 years -Have signs and symptoms of any liver disease -Have a disease or condition known to cause gastrointestinal malabsorption or a known clinically significant gastric emptying abnormality -Have a history of acute or chronic pancreatitis -Currently taking or have taken medications that may cause significant weight gain or promote weight loss within 3 months prior to screening
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percent Change from Baseline in Body Weight [ Time Frame: Baseline, Week 36 | — |
Countries
Argentina, Canada, China, Japan, United States
Contacts
Public ContactTrial Guide Call Center
Eli Lilly Japan K.K.
Outcome results
None listed